|
1
|
Garg PK, Pandey D and Sharma J: The
surgical management of gallbladder cancer. Expert Rev Gastroenterol
Hepatol. 9:155–166. 2015. View Article : Google Scholar
|
|
2
|
Müller BG, De Aretxabala X and González
Domingo M: A review of recent data in the treatment of gallbladder
cancer: what we know, what we do, and what should be done. Am Soc
Clin Oncol Educ Book. e165–e170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu W, Hu Y, Ma Q, Zhou L, Jiang L, Li Z,
Zhao S, Xu Y, Shi W, Li S, et al: miR-223 increases gallbladder
cancer cell sensitivity to docetaxel by downregulating STMN1.
Oncotarget. 7:62364–62376. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dhalluin C, Carlson JE, Zeng L, He C,
Aggarwal AK and Zhou MM: Structure and ligand of a histone
acetyltransferase bromodomain. Nature. 399:491–496. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu Y, Zhou J, Ye F, Xiong H, Peng L, Zheng
Z, Xu F, Cui M, Wei C, Wang X, et al: BRD4 inhibitor inhibits
colorectal cancer growth and metastasis. Int J Mol Sci.
16:1928–1948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Andrieu G, Tran AH, Strissel KJ and Denis
GV: BRD4 regulates breast cancer dissemination through
Jagged1/Notch1 signaling. Cancer Res. 76:6555–6567. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dey A, Chitsaz F, Abbasi A, Misteli T and
Ozato K: The double bromodomain protein Brd4 binds to acetylated
chromatin during interphase and mitosis. Proc Natl Acad Sci USA.
100:8758–8763. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shahbazi J, Liu PY, Atmadibrata B, Bradner
JE, Marshall GM, Lock RB and Liu T: The bromodomain inhibitor JQ1
and the histone deacetylase inhibitor panobinostat synergistically
reduce N-Myc expression and induce anticancer effects. Clin Cancer
Res. 22:2534–2544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu SY, Lee AY, Lai HT, Zhang H and Chiang
CM: Phospho switch triggers Brd4 chromatin binding and activator
recruitment for gene-specific targeting. Mol Cell. 49:843–857.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marcotte R, Sayad A, Brown KR,
Sanchez-Garcia F, Reimand J, Haider M, Virtanen C, Bradner JE,
Bader GD, Mills GB, et al: Functional genomic landscape of human
breast cancer drivers, vulnerabilities, and resistance. Cell.
164:293–309. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sahai V, Kumar K, Knab LM, Chow CR, Raza
SS, Bentrem DJ, Ebine K and Munshi HG: BET bromodomain inhibitors
block growth of pancreatic cancer cells in three-dimensional
collagen. Mol Cancer Ther. 13:1907–1917. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu
JJ and Ding JY: High level of BRD4 promotes non-small cell lung
cancer progression. Oncotarget. 7:9491–9500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meseure D, Vacher S, Alsibai KD, Nicolas
A, Chemlali W, Caly M, Lidereau R, Pasmant E, Callens C and Bieche
I: Expression of ANRIL-polycomb complexes-CDKN2A/B/ARF genes in
breast tumors: Identification of a two-gene (EZH2/CBX7) signature
with independent prognostic value. Mol Cancer Res. 14:623–633.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Z, Chen Y, Wang X, Zhang H, Zhang Y,
Gao Y, Weng M, Wang L, Liang H, Li M, et al: LASP-1 induces
proliferation, metastasis and cell cycle arrest at the G2/M phase
in gallbladder cancer by down-regulating S100P via the PI3K/AKT
pathway. Cancer Lett. 372:239–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bhakar AL, Howell JL, Paul CE, Salehi AH,
Becker EB, Said F, Bonni A and Barker PA: Apoptosis induced by
p75NTR over-expression requires Jun kinase-dependent
phosphorylation of Bad. J Neurosci. 23:11373–11381. 2003.PubMed/NCBI
|
|
16
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Segura MF, Fontanals-Cirera B,
Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez
P, Morante M, Jubierre L, Zhang W, et al: BRD4 sustains melanoma
proliferation and represents a new target for epigenetic therapy.
Cancer Res. 73:6264–6276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimamura T, Chen Z, Soucheray M,
Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi
J, et al: Efficacy of BET bromodomain inhibition in Kras-mutant
non-small cell lung cancer. Clin Cancer Res. 19:6183–6192. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tögel L, Nightingale R, Chueh AC,
Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D,
Dhillon AS, et al: Dual targeting of bromodomain and extraterminal
domain proteins, and WNT or MAPK signaling, inhibits c-MYC
expression and proliferation of colorectal cancer cells. Mol Cancer
Ther. 15:1217–1226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang
M, Wang L, Luo G, Li Y, Zeng F, et al: BRD4 regulates EZH2
transcription through upregulation of C-MYC and represents a novel
therapeutic target in bladder cancer. Mol Cancer Ther.
15:1029–1042. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang H, Liu Y, Xue M, Liu H, Du S, Zhang
L and Wang P: Synergistic action of master transcription factors
controls epithelial-to-mesenchymal transition. Nucleic Acids Res.
44:2514–2527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang
Q, Lin Y, Li J, Kang T, Tao M, et al: Disrupting the interaction of
BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like
breast cancer. Cancer Cell. 25:210–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Li Z, Chu B, Zhang F, Zhang Y, Ke
F, Chen Y, Xu Y, Liu S, Zhao S, et al: Upregulated LASP-1
correlates with a malignant phenotype and its potential therapeutic
role in human cholangiocarcinoma. Tumour Biol. 37:8305–8315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Delbridge AR and Strasser A: The BCL-2
protein family, BH3-mimetics and cancer therapy. Cell Death Differ.
22:1071–1080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kamada H, Nito C, Endo H and Chan PH: Bad
as a converging signaling molecule between survival PI3-K/Akt and
death JNK in neurons after transient focal cerebral ischemia in
rats. J Cereb Blood Flow Metab. 27:521–533. 2007. View Article : Google Scholar
|
